Chief Corporate Development and Strategy Officer · Vistagen Therapeutics, Inc. (VTGN)

Elissa Cote

FY2026 is the first fiscal year CompBrief holds for Elissa Cote as a named executive officer of Vistagen Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2026

$696,134

Salary $320,682Stock awards $0Bonus $35,000

3rd of 5 named executive officers at Vistagen Therapeutics by FY2026 total.

5 named officers on file for Vistagen Therapeutics, FY2026

Elissa Cote’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vistagen Therapeutics’s whole pay program stands against its peers

  • Vistagen Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VTGN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 31, 2026 (DEF 14A).

Free

Get Elissa Cote’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Elissa Cote compensation by year

Vistagen Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Vistagen Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2026
Salary$320,682
Bonus$35,000
Stock awards$0
Option awards$281,925
Non-equity incentive$0
Pension and deferred compensation$0
All other$58,527
Total$696,134

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vistagen Therapeutics, Inc. DEF 14A filed July 31, 2026, accession 0001628280-26-051404, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vistagen Therapeutics, Inc. filed document, accession 0001628280-26-051404. Every figure is read from that document and cited to the page and table it appears in. Filed July 31, 2026.

Equity holdings

unvested awards at FY2026 year-end
TypeUnvested unitsValue at year-endExercise price
Option150,000—$1.96

Per the Outstanding Equity Awards at Fiscal Year-End table in Vistagen Therapeutics, Inc.'s FY2026 proxy; value at the fiscal year-end close, as the company printed it.

Vistagen Therapeutics’s named executive officers, FY2026

as the company reported each
Named executive officerRoleFY2026 total
Shawn SinghPresident, Chief Executive Officer and Director$1,212,560
Nick TresslerChief Financial Officer and Treasurer$866,516
Elissa Cote · this pageChief Corporate Development and Strategy Officer$696,134
Reid AdlerChief Legal Officer$637,520
Joshua PrinceChief Operating Officer$602,520

The full Vistagen Therapeutics compensation record

free company brief

This page is one person within Vistagen Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vistagen Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Elissa Cote's compensation dossier · One-time report. No refunds.